AU2002320013A1 - Human secreted proteins - Google Patents

Human secreted proteins

Info

Publication number: AU2002320013A1
Authority: AU; Australia
Prior art keywords: secreted proteins; human secreted; human; proteins; secreted
Prior art date: 2001-03-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2002320013A

Inventor

Craig A. Rosen

Steven M. Ruben

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Human Genome Sciences Inc

Original Assignee

Human Genome Sciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-21

Filing date

2002-03-19

Publication date

2002-11-18

2002-03-19 Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc

2002-11-18 Publication of AU2002320013A1 publication Critical patent/AU2002320013A1/en

Status Abandoned legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Immunology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Hematology (AREA)
Obesity (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Endocrinology (AREA)
Molecular Biology (AREA)
Emergency Medicine (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

AU2002320013A 2001-03-21 2002-03-19 Human secreted proteins Abandoned AU2002320013A1 (en)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US27734001P	2001-03-21	2001-03-21
US60/277,340		2001-03-21
US30617101P	2001-07-19	2001-07-19
US60/306,171		2001-07-19
US33128701P	2001-11-13	2001-11-13
US60/331,287		2001-11-13
PCT/US2002/008279 WO2002090526A2 (en)	2001-03-21	2002-03-19	Human secreted proteins

Publications (1)

Publication Number	Publication Date
AU2002320013A1 true AU2002320013A1 (en)	2002-11-18

Family

ID=27402891

Family Applications (6)

Application Number	Title	Priority Date	Filing Date
AU2002332391A Abandoned AU2002332391A1 (en)	2001-03-21	2002-03-19	Human secreted proteins
AU2002320013A Abandoned AU2002320013A1 (en)	2001-03-21	2002-03-19	Human secreted proteins
AU2002324424A Abandoned AU2002324424A1 (en)	2001-03-21	2002-03-19	Human secreted proteins
AU2002363296A Abandoned AU2002363296A1 (en)	2001-03-21	2002-03-19	Human secreted proteins
AU2002354719A Abandoned AU2002354719A1 (en)	2001-03-21	2002-03-19	Human secreted proteins
AU2002326293A Abandoned AU2002326293A1 (en)	2001-03-21	2002-03-19	Human secreted proteins

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AU2002332391A Abandoned AU2002332391A1 (en)	2001-03-21	2002-03-19	Human secreted proteins

Family Applications After (4)

Application Number	Title	Priority Date	Filing Date
AU2002324424A Abandoned AU2002324424A1 (en)	2001-03-21	2002-03-19	Human secreted proteins
AU2002363296A Abandoned AU2002363296A1 (en)	2001-03-21	2002-03-19	Human secreted proteins
AU2002354719A Abandoned AU2002354719A1 (en)	2001-03-21	2002-03-19	Human secreted proteins
AU2002326293A Abandoned AU2002326293A1 (en)	2001-03-21	2002-03-19	Human secreted proteins

Country Status (4)

Country	Link
EP (7)	EP1414845A4 (en)
AU (6)	AU2002332391A1 (en)
CA (7)	CA2441840A1 (en)
WO (7)	WO2003004622A2 (en)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7196164B2 (en)	1997-07-08	2007-03-27	Human Genome Sciences, Inc.	Secreted protein HHTLF25
CA2295474A1 (en)	1997-07-08	1999-01-21	Human Genome Sciences, Inc.	123 human secreted proteins
US20060052321A1 (en)	2002-04-05	2006-03-09	Raitano Arthur B	Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US6833438B1 (en)	1999-06-01	2004-12-21	Agensys, Inc.	Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20040141975A1 (en)	1998-06-01	2004-07-22	Raitano Arthur B.	Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US20030149531A1 (en)	2000-12-06	2003-08-07	Hubert Rene S.	Serpentine transmembrane antigens expressed in human cancers and uses thereof
ES2329851T3 (en)	1998-06-01	2009-12-01	Agensys, Inc.	NEW TRANSMEMBRANABLE ANTIGENS EXPRESSED IN HUMAN CANCER AND USING THEMSELVES.
EE200100372A (en)	1999-01-15	2002-10-15	Biogen, Incorporated	TWEAK Protein and TWEAK Protein Receptor Antagonists and Their Use in the Treatment of Immune Diseases
EP1666490A3 (en) *	2000-07-25	2006-11-02	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7291719B2 (en)	2000-07-25	2007-11-06	Genentech, Inc.	PRO4332 antibodies
AU2002243444A1 (en)	2000-10-31	2002-06-24	Diadexus, Inc.	Compositions and methods relating to colon specific genes and proteins
US20020111302A1 (en) *	2000-11-30	2002-08-15	Y. Tom Tang	Novel nucleic acids and polypeptides
AU2002318112B2 (en)	2001-04-10	2007-12-06	Agensys, Inc.	Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
US20030100497A1 (en)	2001-06-20	2003-05-29	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US7494646B2 (en)	2001-09-06	2009-02-24	Agensys, Inc.	Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
JP2005505271A (en)	2001-09-06	2005-02-24	アジェンシス，インコーポレイテッド	Nucleic acids and corresponding proteins given the name STEAP-1 useful in the treatment and detection of cancer
CA2463596A1 (en)	2001-10-12	2003-04-24	Yamanouchi Pharmaceutical Co., Ltd.	Method of screening cell death inhibitor
CN106421778A (en)	2002-04-09	2017-02-22	比奥根Ma公司	Methods for treating tweak-related conditions
AU2003900747A0 (en) *	2003-02-18	2003-03-06	Garvan Institute Of Medical Research	Diagnosis and treatment of pancreatic cancer
US7709610B2 (en)	2003-05-08	2010-05-04	Facet Biotech Corporation	Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en)	2003-05-08	2005-02-03	Protein Design Laboratories, Inc.	Therapeutic use of anti-CS1 antibodies
WO2005019258A2 (en) *	2003-08-11	2005-03-03	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
WO2005030039A2 (en) *	2003-09-23	2005-04-07	University Of North Carolina At Chapel Hill	Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin k epoxide reductase gene and warfarin dosage
ATE540107T1 (en) *	2003-10-14	2012-01-15	Baxter Int	VKORC1 (VITAMIN K EPOXIDE RECYCLING POLYPEPTIDE), A THERAPEUTIC TARGET FOR COUMARIN AND THEIR DERIVATIVES
WO2005076003A2 (en) *	2004-02-03	2005-08-18	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with plasma glutamate carboxypeptidase (pgcp)
US20050186577A1 (en)	2004-02-20	2005-08-25	Yixin Wang	Breast cancer prognostics
US8008442B2 (en)	2004-04-22	2011-08-30	Agensys, Inc.	Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
KR101268877B1 (en)	2004-09-01	2013-05-31	다이나박스 테크놀로지 코퍼레이션	Methods and compositions for inhibition of innate immune responses and autoimmunity
WO2006026807A1 (en) *	2004-09-07	2006-03-16	Telethon Institute For Child Health Research	Agents for treatment or prevention of an allergic disorder
EP1799850A4 (en) *	2004-09-07	2009-02-11	Telethon Inst For Child Health	METHOD OF DIAGNOSING AND / OR PREDICTING DEVELOPMENT OF ALLERGIC DISEASE
US20090124993A1 (en)	2005-02-17	2009-05-14	Burkly Linda C	Treating neurological disorders
CN101124320A (en)	2005-02-28	2008-02-13	巴克斯特国际公司	Recombinant co-expression of vitamin K epoxide reductase subunit 1 to increase vitamin K dependent protein expression
CA2601574C (en)	2005-03-15	2014-12-02	University Of North Carolina At Chapel Hill	Methods and compositions for producing active vitamin k-dependent proteins
ES2432564T3 (en)	2005-05-10	2013-12-04	Biogen Idec Ma Inc.	Treatment and evaluation of inflammatory disorders
WO2006138219A2 (en)	2005-06-13	2006-12-28	Biogen Idec Ma Inc.	Methods of diagnosis / prognosis of inflammatory conditions
CA2620809A1 (en) *	2005-09-01	2007-03-08	Howard Florey Institute Of Experimental Physiology And Medicine	Prophylactic and therapeutic agents and uses therefor
GB0521488D0 (en) *	2005-10-21	2005-11-30	Ares Trading Sa	Integral membrane protein
US7572618B2 (en)	2006-06-30	2009-08-11	Bristol-Myers Squibb Company	Polynucleotides encoding novel PCSK9 variants
DK2061814T3 (en)	2006-10-27	2012-08-27	Genentech Inc	Antibodies and immunoconjugates and their use.
EP2083861A4 (en)	2006-11-07	2010-11-24	Merck Sharp & Dohme	Antagonists of pcsk9
US8093222B2 (en)	2006-11-27	2012-01-10	Isis Pharmaceuticals, Inc.	Methods for treating hypercholesterolemia
WO2008118386A2 (en) *	2007-03-27	2008-10-02	Merck & Co., Inc.	Method for detecting autoprocessed, secreted pcsk9
JOP20080381B1 (en)	2007-08-23	2023-03-28	Amgen Inc	Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9)
EP2209896B1 (en)	2007-10-26	2017-03-01	Dynavax Technologies Corporation	Methods and compositions for inhibition of immune responses and autoimmunity
CN101932728B (en) *	2007-11-30	2013-06-19	西门子医疗保健诊断公司	Adiponectin receptor fragments and methods of use
AR070316A1 (en)	2008-02-07	2010-03-31	Merck & Co Inc	PCSK9 ANTAGONISTS (SUBTILISINE-KEXINA TYPE 9 PROPROTEIN)
AR070315A1 (en)	2008-02-07	2010-03-31	Merck & Co Inc	ANTIBODIES 1B20 ANTAGONISTS OF PCSK9
WO2010068526A1 (en)	2008-12-12	2010-06-17	Merck Sharp & Dohme Corp.	Pcsk9 immunoassay
AU2010313324A1 (en)	2009-10-30	2012-04-12	Merck Sharp & Dohme Corp.	AX213 and AX132 PCSK9 antagonists and variants
WO2011053759A1 (en)	2009-10-30	2011-05-05	Merck Sharp & Dohme Corp.	Ax1 and ax189 pcsk9 antagonists and variants
MX338980B (en)	2010-06-16	2016-05-06	Dynavax Tech Corp	Methods of treatment using tlr7 and/or tlr9 inhibitors.
CN103209987B (en)	2010-09-22	2017-06-06	艾丽奥斯生物制药有限公司	substituted nucleotide analogs
WO2012088222A2 (en)	2010-12-21	2012-06-28	The University Of North Carolina At Chapel Hill	Methods and compositions for producing active vitamin k-dependent proteins
EP2794630A4 (en)	2011-12-22	2015-04-01	Alios Biopharma Inc	Substituted phosphorothioate nucleotide analogs
WO2013142124A1 (en)	2012-03-21	2013-09-26	Vertex Pharmaceuticals Incorporated	Solid forms of a thiophosphoramidate nucleotide prodrug
WO2013142157A1 (en)	2012-03-22	2013-09-26	Alios Biopharma, Inc.	Pharmaceutical combinations comprising a thionucleotide analog
US8986691B1 (en)	2014-07-15	2015-03-24	Kymab Limited	Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9017678B1 (en)	2014-07-15	2015-04-28	Kymab Limited	Method of treating rheumatoid arthritis using antibody to IL6R
US9051378B1 (en)	2014-07-15	2015-06-09	Kymab Limited	Targeting rare human PCSK9 variants for cholesterol treatment
US9034332B1 (en)	2014-07-15	2015-05-19	Kymab Limited	Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9067998B1 (en)	2014-07-15	2015-06-30	Kymab Limited	Targeting PD-1 variants for treatment of cancer
US8992927B1 (en)	2014-07-15	2015-03-31	Kymab Limited	Targeting human NAV1.7 variants for treatment of pain
US8945560B1 (en)	2014-07-15	2015-02-03	Kymab Limited	Method of treating rheumatoid arthritis using antibody to IL6R
US9023359B1 (en)	2014-07-15	2015-05-05	Kymab Limited	Targeting rare human PCSK9 variants for cholesterol treatment
US8883157B1 (en)	2013-12-17	2014-11-11	Kymab Limited	Targeting rare human PCSK9 variants for cholesterol treatment
US9045545B1 (en)	2014-07-15	2015-06-02	Kymab Limited	Precision medicine by targeting PD-L1 variants for treatment of cancer
US8980273B1 (en)	2014-07-15	2015-03-17	Kymab Limited	Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986694B1 (en)	2014-07-15	2015-03-24	Kymab Limited	Targeting human nav1.7 variants for treatment of pain
US9914769B2 (en)	2014-07-15	2018-03-13	Kymab Limited	Precision medicine for cholesterol treatment
US9045548B1 (en)	2014-07-15	2015-06-02	Kymab Limited	Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9682218B2 (en)	2013-12-23	2017-06-20	Carefusion 2200, Inc.	Pleurodesis device and method
GB201403775D0 (en)	2014-03-04	2014-04-16	Kymab Ltd	Antibodies, uses & methods
US9139648B1 (en)	2014-07-15	2015-09-22	Kymab Limited	Precision medicine by targeting human NAV1.9 variants for treatment of pain
US9150660B1 (en)	2014-07-15	2015-10-06	Kymab Limited	Precision Medicine by targeting human NAV1.8 variants for treatment of pain
WO2017220988A1 (en)	2016-06-20	2017-12-28	Kymab Limited	Multispecific antibodies for immuno-oncology
EP3534947A1 (en)	2016-11-03	2019-09-11	Kymab Limited	Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018119354A1 (en)	2016-12-23	2018-06-28	President And Fellows Of Harvard College	Gene editing of pcsk9
SG11201909218RA (en)	2017-04-03	2019-11-28	Hoffmann La Roche	Antibodies binding to steap-1
CN110719968A (en)	2017-06-22	2020-01-21	宝洁公司	Film comprising a water-soluble layer and a vapor-deposited inorganic coating
ES2963042T3 (en)	2017-06-22	2024-03-25	Procter & Gamble	Films that include a water-soluble layer and an organic vapor-deposited coating
EP4133072A4 (en)	2020-04-09	2024-11-06	Verve Therapeutics, Inc.	CHEMICALLY MODIFIED GUIDE RNAS FOR GENOME EDITING WITH CAS9

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100236393B1 (en) *	1996-02-02	1999-12-15	나까니시 히로유끼	A pharmaceutical preparation containing a human growth hormone
WO2002026931A2 (en) *	2000-09-25	2002-04-04	Human Genome Sciences, Inc.	71 human secreted proteins
US5858716A (en) *	1997-05-30	1999-01-12	Smithkline Beecham Corporation	H2CAA71 polynucleotides
CA2333917A1 (en) *	1998-07-15	2000-01-27	Human Genome Sciences, Inc.	71 human secreted proteins

2002
- 2002-03-19 CA CA002441840A patent/CA2441840A1/en not_active Abandoned
- 2002-03-19 WO PCT/US2002/008124 patent/WO2003004622A2/en not_active Ceased
- 2002-03-19 CA CA002441417A patent/CA2441417A1/en not_active Abandoned
- 2002-03-19 AU AU2002332391A patent/AU2002332391A1/en not_active Abandoned
- 2002-03-19 EP EP02782476A patent/EP1414845A4/en not_active Withdrawn
- 2002-03-19 CA CA002441755A patent/CA2441755A1/en not_active Abandoned
- 2002-03-19 WO PCT/US2002/009785 patent/WO2002095010A2/en not_active Ceased
- 2002-03-19 AU AU2002320013A patent/AU2002320013A1/en not_active Abandoned
- 2002-03-19 AU AU2002324424A patent/AU2002324424A1/en not_active Abandoned
- 2002-03-19 AU AU2002363296A patent/AU2002363296A1/en not_active Abandoned
- 2002-03-19 AU AU2002354719A patent/AU2002354719A1/en not_active Abandoned
- 2002-03-19 EP EP02759068A patent/EP1404702A4/en not_active Withdrawn
- 2002-03-19 EP EP02799146A patent/EP1390390A4/en not_active Withdrawn
- 2002-03-19 EP EP02760994A patent/EP1379132A4/en not_active Withdrawn
- 2002-03-19 AU AU2002326293A patent/AU2002326293A1/en not_active Abandoned
- 2002-03-19 EP EP02780789A patent/EP1423134A2/en not_active Withdrawn
- 2002-03-19 EP EP02723499A patent/EP1379264A4/en not_active Withdrawn
- 2002-03-19 WO PCT/US2002/008277 patent/WO2003038063A2/en not_active Ceased
- 2002-03-19 WO PCT/US2002/008123 patent/WO2002102993A2/en not_active Ceased
- 2002-03-19 CA CA002441416A patent/CA2441416A1/en not_active Abandoned
- 2002-03-19 WO PCT/US2002/008276 patent/WO2002076488A1/en not_active Ceased
- 2002-03-19 CA CA002441397A patent/CA2441397A1/en not_active Abandoned
- 2002-03-19 WO PCT/US2002/008278 patent/WO2002102994A2/en not_active Ceased
- 2002-03-19 CA CA002441832A patent/CA2441832A1/en not_active Abandoned
- 2002-03-19 EP EP02749512A patent/EP1381622A2/en not_active Withdrawn
- 2002-03-19 CA CA002441702A patent/CA2441702A1/en not_active Abandoned
- 2002-03-19 WO PCT/US2002/008279 patent/WO2002090526A2/en not_active Ceased

Also Published As

Publication number	Publication date
EP1379132A2 (en)	2004-01-14
WO2002102994A2 (en)	2002-12-27
EP1379132A4 (en)	2009-07-01
CA2441832A1 (en)	2002-12-27
EP1414845A4 (en)	2009-07-08
CA2441755A1 (en)	2003-05-08
AU2002332391A1 (en)	2003-01-02
AU2002324424A1 (en)	2002-12-03
WO2003038063A2 (en)	2003-05-08
EP1379264A1 (en)	2004-01-14
EP1381622A2 (en)	2004-01-21
AU2002363296A1 (en)	2003-05-12
WO2002090526A2 (en)	2002-11-14
WO2002090526A3 (en)	2003-10-30
CA2441416A1 (en)	2003-01-16
WO2002102994A3 (en)	2003-07-24
AU2002354719A1 (en)	2003-01-21
WO2002102993A3 (en)	2004-03-25
WO2003038063A3 (en)	2003-12-11
CA2441702A1 (en)	2002-12-27
AU2002326293A1 (en)	2003-01-02
EP1390390A2 (en)	2004-02-25
EP1404702A2 (en)	2004-04-07
EP1423134A2 (en)	2004-06-02
WO2002076488A1 (en)	2002-10-03
CA2441840A1 (en)	2002-11-28
EP1404702A4 (en)	2009-07-08
WO2003004622A3 (en)	2004-02-19
EP1390390A4 (en)	2009-07-08
CA2441417A1 (en)	2002-11-14
WO2002095010A3 (en)	2004-02-12
CA2441397A1 (en)	2002-10-03
WO2002102993A2 (en)	2002-12-27
WO2002095010A2 (en)	2002-11-28
WO2003004622A2 (en)	2003-01-16
EP1379264A4 (en)	2009-07-08
EP1414845A2 (en)	2004-05-06

Publication	Publication Date	Title
AU2002332391A1 (en)	2003-01-02	Human secreted proteins
AU2002309513A1 (en)	2002-10-08	Human secreted proteins
AU2002361452A1 (en)	2003-07-09	Secreted proteins
AU2002232596A1 (en)	2002-06-24	Secreted human proteins
AU2002353227A1 (en)	2003-07-15	Secreted proteins
AU2002342010A1 (en)	2003-04-14	Secreted proteins
AU2002354803A1 (en)	2003-01-21	Secreted proteins
AU2003301843A1 (en)	2004-06-07	157 human secreted proteins
AU2002252700A1 (en)	2002-11-05	Secreted proteins
AU2002255733A1 (en)	2002-09-19	Secreted proteins
AU2001294719A1 (en)	2002-04-08	Secreted human proteins
AU2002365153A1 (en)	2003-06-30	41 human secreted proteins
AU2002258657A1 (en)	2002-10-15	Secreted proteins
AU2002327533A1 (en)	2003-03-03	Secreted proteins
AU2002327176A1 (en)	2002-12-16	20 human secreted proteins
AU2002246998A1 (en)	2002-07-30	50 human secreted proteins
AU2002348034A1 (en)	2003-05-12	16 human secreted proteins
AU2002254275A1 (en)	2002-10-08	Human secreted proteins
AU2003211137A1 (en)	2003-09-09	20 human secreted proteins
AU2002257630A1 (en)	2002-09-24	Human mrp5-like protein
AU2002247189A1 (en)	2002-09-12	70 human secreted proteins
AU2002253985A1 (en)	2002-09-12	83 human secreted proteins
AU2002332483A1 (en)	2003-02-24	13 human secreted proteins
AU2002352912A1 (en)	2003-06-10	Secreted proteins
AU2002247042A1 (en)	2002-08-19	Secreted proteins

Legal Events

Date	Code	Title	Description
2004-02-19	MK6	Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase